$INGN

Yi Boyer Jennifer M sold $70K of INGN

Yi Boyer Jennifer M (EVP Entrprs Enblmnt, Ch HR Off) sold 10,770 shares of Inogen Inc (INGN) at $6.53 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yi Boyer Jennifer M
Published Jun 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INGN
Neutral
high confidence
Mentioned
$INGN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INGNNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company fundamentals, guidance, or external catalysts.

02

Market read

Traders may note the insider sale for sentiment, but the pre-arranged nature limits actionable fundamental implications.

03

What to watch

The sale size is modest relative to typical institutional flows, and the 10b5-1 structure reduces interpretability versus discretionary selling.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-02, transaction dated 2026-05-29

Background

The article is an SEC Form 4 insider transaction disclosure for Inogen, reported via EDGAR.

Company-level read

Ticker impact

$INGNNeutralHigh confidence
Context

Inogen Form 4 shows EVP Yi Boyer Jennifer M sold 10,770 shares at $6.5286 on a 10b5-1 plan, totaling $70,313.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and provides no new operating, guidance, or regulatory information.

Market effects

No clear sector read-through; this is company-specific insider trading with no disclosed business change.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term valuation risk, so traders may still watch for follow-on selling.

Key entities

  • Inogen Inc

    Subject of the Form 4 insider transaction disclosure.

  • Yi Boyer Jennifer M

    EVP Entrprs Enblmnt, Ch HR Off who executed the sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INGNMedAI 8/10

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen (NASDAQ:INGN) reported Q2 results with improving profitability and continued international growth, but weakness in the US oxygen rental and direct-to-consumer channels. International revenue was $41.3M (+15% YoY). US sales fell 2% to $42.3M and rental revenue dropped 12% to $11.6M. Full-year 2026 revenue guidance was cut to $355M-$361M.

$INGNMedAI 9/10

Inogen (INGN) Q2 2026 Earnings Call Transcript

Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.

$INGNMedAI 8/10

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Inogen (INGN) cut its 2026 revenue outlook to $355 million to $361 million from $366 million to $373 million after Q2 results showed ongoing U.S. channel pressure. Q2 U.S. sales fell 2.3% to $42.3M and U.S. rentals fell 11.8% to $11.6M, while international revenue rose 14.8% to $41.3M. Adjusted gross margin rose to 45.6%.

$INGNHigh

Inogen Inc (INGN): Results of Operations and Financial Condition

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN ), a medical technolog